◀ Back to NOS3
CRH — NOS3
Text-mined interactions from Literome
Cantarella et al., Br J Pharmacol 2001
:
Divergent
effects of
corticotropin releasing hormone on endothelial cell
nitric oxide synthase are associated with different expression of CRH type 1 and 2 receptors
Ralph et al., Am J Pathol 2007
(Arthritis...) :
CRH enhanced the expression of
nitric-oxide synthase ( NOS III ) to promote NO production from CRH-R1alpha expressing cells
Jain et al., Am J Obstet Gynecol 1997
:
The relaxation induced by corticotropin releasing factor in aortic rings from nonpregnant rats decreased after deendothelization and treatment with N omega-nitro-L-arginine methyl ester ( a
nitric oxide synthase inhibitor ), LY-83,583 ( a guanylate cyclase inhibitor ), or alpha-helical
corticotropin releasing factor 9-41 ( a corticotropin releasing factor antagonist )
Raber et al., Brain research. Brain research reviews 1998
(Disease Models, Animal...) :
The IFNalpha stimulated release of AVP and
CRH appears to be mediated by cyclic GMP production, and this release by IFNalpha and IL-2 may be
mediated in part by activation of constitutive
nitric oxide synthase
Tomikawa et al., Am J Physiol 1998
(Kidney Failure, Chronic) :
CRF significantly decreased endothelial NOS (eNOS) mRNA abundance by 53 % ( P < 0.01 ) and
reduced expression of
eNOS protein by 42 % ( P < 0.01 ) compared with the controls